iOur case series showed that uncomplicated Yarrowia lipolytica fungemia might be treated with catheter removal alone. The Vitek 2 YST identification (ID) card system, matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), and internal transcribed spacer and 25S nuclear ribosomal DNA (nrDNA) gene sequencing provided reliable identification. All isolates had low MICs to voriconazole, echinocandins, and amphotericin B.A growing number of non-albicans Candida spp. have emerged in recent years as important human pathogens among the growing, heterogeneous population of immunocompromised and critically ill patients (1-3). Yarrowia lipolytica (Candida lipolytica) is an ascomycetous yeast found ubiquitously in the environment and meat products, including sausages and dairy products, especially cheese (4). It may occasionally be found as a colonizer in the feces, oropharyngeal swabs, sputa, and skin swabs of asymptomatic persons (5). Its intense secretory activity is widely employed in the food, detergent, and pharmaceutical industries to produce aroma compounds, organic acids, polyalcohols, emulsifiers, and surfactants (4, 6, 7). Although Y. lipolytica was previously considered to be of low virulence, it has been increasingly recognized to cause sporadic cases and nosocomial clusters of human infections, especially catheter-related suppurative thrombophlebitis and fungemia associated with biofilm formation in immunocompromised or critically ill patients who experience prolonged hospitalization and who required longdwelling intravascular catheterization and broad-spectrum antibacterial agents (5,(8)(9)(10). Other forms of clinical disease, including noncatheter-related fungemia, traumatic ocular infection, and acute exacerbation of chronic sinusitis, have also been reported (5, 8, 11). A major limitation of the literature on Y. lipolytica infection is that most studies were case reports or small case series focusing only on clinical characteristics (5,(8)(9)(10)(11)(12)(13)(14)(15)(16)(17). Recently, Trabelsi and colleagues reported the epidemiological risk factors and clinical outcomes of 55 cases of Y. lipolytica fungemia in Tunisia and provided some data on the in vitro susceptibility test results of the isolates to a few antifungal drugs (6). However, details about the correlative microbiological characteristics, including phenotypic and genotypic identification and in vitro susceptibility test results for newer antifungal drugs such as the echinocandins and posaconazole, were lacking in this larger case series. In this multicenter, prospective surveillance study in China, we described the epidemiological and clinical characteristics of 14 cases of Y. lipolytica fungemia in correlation with the comparative performance of several commonly employed phenotypic and genotypic identification methods, and we also described the in vitro susceptibility of this emerging fungal pathogen to nine antifungal drugs, including the newer azoles and echinocandins.This study was approved by the Inst...